These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37722519)

  • 1. Modulation of the nitric oxide/cGMP pathway in cardiac contraction and relaxation: Potential role in heart failure treatment.
    Mollace R; Scarano F; Bava I; Carresi C; Maiuolo J; Tavernese A; Gliozzi M; Musolino V; Muscoli S; Palma E; Muscoli C; Salvemini D; Federici M; Macrì R; Mollace V
    Pharmacol Res; 2023 Oct; 196():106931. PubMed ID: 37722519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
    Breitenstein S; Roessig L; Sandner P; Lewis KS
    Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction.
    Aimo A; Castiglione V; Vergaro G; Panichella G; Senni M; Lombardi CM; Emdin M
    Heart Fail Rev; 2022 Jul; 27(4):1165-1171. PubMed ID: 34291399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplicity of Nitric Oxide and Natriuretic Peptide Signaling in Heart Failure.
    Preedy MEJ; Baliga RS; Hobbs AJ
    J Cardiovasc Pharmacol; 2020 May; 75(5):370-384. PubMed ID: 31498237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of endothelial dysfunction in heart failure.
    Zuchi C; Tritto I; Carluccio E; Mattei C; Cattadori G; Ambrosio G
    Heart Fail Rev; 2020 Jan; 25(1):21-30. PubMed ID: 31686283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
    Paulus WJ; Tschöpe C
    J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction.
    van Heerebeek L; Hamdani N; Falcão-Pires I; Leite-Moreira AF; Begieneman MP; Bronzwaer JG; van der Velden J; Stienen GJ; Laarman GJ; Somsen A; Verheugt FW; Niessen HW; Paulus WJ
    Circulation; 2012 Aug; 126(7):830-9. PubMed ID: 22806632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vericiguat for Heart Failure with Reduced Ejection Fraction.
    Lombardi CM; Cimino G; Pagnesi M; Dell'Aquila A; Tomasoni D; Ravera A; Inciardi R; Carubelli V; Vizzardi E; Nodari S; Emdin M; Aimo A
    Curr Cardiol Rep; 2021 Aug; 23(10):144. PubMed ID: 34410527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.
    Mátyás C; Németh BT; Oláh A; Török M; Ruppert M; Kellermayer D; Barta BA; Szabó G; Kökény G; Horváth EM; Bódi B; Papp Z; Merkely B; Radovits T
    Eur J Heart Fail; 2017 Mar; 19(3):326-336. PubMed ID: 27995696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study.
    Zhao D; Guallar E; Vaidya D; Ndumele CE; Ouyang P; Post WS; Lima JA; Ying W; Kass DA; Hoogeveen RC; Shah SJ; Subramanya V; Michos ED
    J Am Heart Assoc; 2020 Jan; 9(2):e013966. PubMed ID: 31928156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Right ventricular and cyclic guanosine monophosphate signalling abnormalities in stages B and C of heart failure with preserved ejection fraction.
    Petit T; Claessen G; Claeys M; La Gerche A; Claus P; Ghysels S; Delcroix M; Ciarka A; Droogne W; Van Cleemput J; Willems R; Voigt JU; Bogaert J; Janssens S
    ESC Heart Fail; 2021 Dec; 8(6):4661-4673. PubMed ID: 34477327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitrite therapy improves left ventricular function during heart failure via restoration of nitric oxide-mediated cytoprotective signaling.
    Bhushan S; Kondo K; Polhemus DJ; Otsuka H; Nicholson CK; Tao YX; Huang H; Georgiopoulou VV; Murohara T; Calvert JW; Butler J; Lefer DJ
    Circ Res; 2014 Apr; 114(8):1281-91. PubMed ID: 24599803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial expression of somatotropic axis, adrenergic signalling, and calcium handling genes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction.
    D'Assante R; Arcopinto M; Rengo G; Salzano A; Walser M; Gambino G; Monti MG; Bencivenga L; Marra AM; Åberg DN; De Vincentiis C; Ballotta A; Bossone E; Isgaard J; Cittadini A
    ESC Heart Fail; 2021 Apr; 8(2):1681-1686. PubMed ID: 33512777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction.
    Cordwin DJ; Berei TJ; Pogue KT
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):593-600. PubMed ID: 34487435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Therapeutics for Heart Failure: Focusing on cGMP Signaling.
    Mangmool S; Duangrat R; Parichatikanond W; Kurose H
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week.
    Emdin M; Aimo A; Castiglione V; Vergaro G; Georgiopoulos G; Saccaro LF; Lombardi CM; Passino C; Cerbai E; Metra M; Senni M
    J Am Coll Cardiol; 2020 Oct; 76(15):1795-1807. PubMed ID: 33032741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current trends and future perspectives for heart failure treatment leveraging cGMP modifiers and the practical effector PKG.
    Nakamura T; Tsujita K
    J Cardiol; 2021 Oct; 78(4):261-268. PubMed ID: 33814252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction.
    Konstantinou DM; Chatzizisis YS; Giannoglou GD
    Pharmacol Ther; 2013 Nov; 140(2):156-66. PubMed ID: 23792088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction.
    Franssen C; Chen S; Unger A; Korkmaz HI; De Keulenaer GW; Tschöpe C; Leite-Moreira AF; Musters R; Niessen HW; Linke WA; Paulus WJ; Hamdani N
    JACC Heart Fail; 2016 Apr; 4(4):312-24. PubMed ID: 26682792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zhenwu decoction ameliorates cardiac hypertrophy through activating sGC (soluble guanylate cyclase) - cGMP (cyclic guanosine monophosphate) - PKG (protein kinase G) pathway.
    Chen L; Zhou X; Deng Y; Yang Y; Chen X; Chen Q; Liu Y; Fu X; Kwan HY; You Y; Jin W; Zhao X
    J Ethnopharmacol; 2023 Jan; 300():115705. PubMed ID: 36099983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.